Species covered: cattle, sheep, swine, horse, avian.Pet diagnostic products are under development.

1.Support from R&D technology platform：
·Pure, stable and efficient antigens and antibodies
·Adequate supply of raw materials

2.Support from animal experiment platform：
·Supply of reference material and clinical sample
·Detection, monitoring and differential diagnosis

3.Advanced production line:
·Two GMP production lines for immunological & molecular biology diagnostics（The company’s GMP production facilities cover an area of approximately 1780 m², with two specialized GMP production lines for immunology and molecular biology. Equipped with advanced production equipment and operated by skilled technical staff, the facilities are supported by a rigorous quality control system, ensuring more efficient output and greater product stability.）
·Introducing automated mass production processes

Leading technologies in virus amplification, antigen purification, antigen determination, and antigen preservation.

The platform advantages :
1.Double-strain Reverse Genetic Technology
2.Double Efficient Suspension Culture Technology
3.Double Membrane Integrated Purification Technology
4.Bidirectional Antigen Protection Technology
5.Double 146S Measurement Technology

For the first time in the world, synthetic peptide technology was applied to prophylactic biological products.
1.Platform Advantages：
① Design and construction of ultra-long chain synthetic polypeptide
② Difficult Peptide” preparation process developed
③ Coupling and modification technology of antigen peptides and proteins
④ High purity and high yield with industrial-scale polypeptide preparation and purification technology

2.Ultra-long chain refers to the screening, design, and construction of synthetic polypeptide vaccines; preparation process development for "Difficult Peptides".

3. Planned Projects
① Alzheimer's Disease Synthetic Polypeptide Vaccine Production (Treatment and Prevention)
② Pet and Pig Castration Vaccine
③ Developing human and animal polypeptide hormone drugs, hand-foot-and-mouth disease vaccines, etc.

4.Land Expansion Project
·Planning to build a fully automated polypeptide GMP production line, which will further expand the automated production capacity for large-chain and ultra-long-chain polypeptides.

Platform Advantages：

1. Antigen sequence design method based on big data

2. Efficient construction technology of protein expression

3. Nanovaccine technology
① Click chemistry enables modular production
② Universal technology allows rapid preparation
③ High stability and high efficiency

4. Biomimetics affinity chromatography

5. Intelligent molecular staple technology

Circular RNA technology, known as mRNA technology Version 2.0, offers superior advantages in production, delivery, and treatment.

Breakthrough 1: Circular RNA Bottom Layer Patent Platform (Clean-PIE)
①· Circular RNA: Second-generation mRNA technology, mRNA 2.0 version.
② · Co-introduces circular structures, protecting itself from nuclease degradation, making it more stable.
③ · Completely free from linear mRNA restrictions (no capping, no polyA, no modification).
④· Protein expression is long-lasting with ultra-long-chain mRNA, leading to stronger T-cell immune responses.
⑤· Clean-PIE circularization technology has independent intellectual property rights, high success rate, and does not introdu ce exogenous sequences

Breakthrough 2: Screening Novel Cationic Lipids with Independent Intellectual Property Rights; In-house Production of Core Cationic Lipids, Effectively Reducing Costs

Breakthrough 3: Shenlian Biomedical Circular RNA Vaccine GMP Production Workshop Construction
①·The Circular RNA vaccine GMP production workshop is currently under construction.
② ·The total building area is 3614 m², with a cleanroom area of 2222 m².
③· It is projected to complete construction and undergo GMP static inspection in early 2025.
④· Scaling up the industrial production of mRNA vaccine products, from pilot scale to commercial production.
⑤· Establishment and operation of a GMP system for vaccine production, enabling large-scale mass production capacity for Circular RNA vaccines and therapeutic products.

Breakthrough 4:Rabies Virus mRNA Vaccine Demonstrates Significantly Superior Immunogenic Efficacy Compared to Commercial Inactivated Vaccines